An observational study in Hereditary Spastic Paraplegia, SPG47 and SPG50, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged Up to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Boston Children's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Spastic Paraplegia, Hereditary with a site in United States — 7 open to participants now, 10 under way, none of them phase 3. Spastic Paraplegia, Hereditary · United States.
Among the 18 studies in Spastic Paraplegia, Hereditary with a site in United States, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2020, is one of 11 observational ones, and was the 6th registered.
51 studies on the registry are indexed under Spastic Paraplegia, Hereditary; 20 are open to participants now.
Browse Spastic Paraplegia, Hereditary studies →7 of the 18 studies in Spastic Paraplegia, Hereditary with a site in United States are open now. Recruiting first, the newest first:
Rahul Sachdeva · Sites in United States
Ages 18+
Boston Children's Hospital · Sites in United States
University of California, San Diego · Sites in United States
Boston Children's Hospital · Sites in United States
Ages 1 mo–30 yrs
University of Washington · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Spastic Paraplegia, Hereditary studies recruiting now, 10 (59%) set no upper age limit and 7 (41%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.
This study: Up to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2020.
This study's planned enrollment of 700 is above the median of 100 across 25 observational studies indexed under Spastic Paraplegia, Hereditary.
Median enrollment 9 across the 7 interventional studies, 200 across the 11 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 3 studies filed under Spastic Paraplegia, Hereditary — fewer than ten, so there is no comparison to draw.
3 of the studies in Spastic Paraplegia, Hereditary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05848271University of California, San DiegoNatural History Study of Patients with HPDL Mutations | 2026-12-31 |
| NCT05354622Boston Children's HospitalHereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) | 2027-04-29 |
| NCT07930481University of WashingtonNon-invasive Spinal Stimulation for Gait in Genetic Spasticity | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Spastic Paraplegia, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) is focused on gathering longitudinal clinical data as well as biological samples (skin and/or blood and/or saliva) from male and female patients, under the age of 30, who exhibited early onset symptoms of HSP with (1) a clinical diagnosis of hereditary spastic paraplegia and (2) the presence of variants in HSP related genes and/or be a relative of a person with such a diagnosis. Currently, the treatment for this disorder is generally symptomatic and available therapies improve quality of life, but are grossly inefficient in slowing the disease progression. Access to the registry information will be limited to the study staff who are responsible for recruitment and maintenance of the registry. We hope that recruitment into the registry for studies will advance knowledge of the causes, clinical course, diagnosis, and treatment of these conditions.
The hereditary spastic paraplegias (HSP) are a group of more than 80 neurodegenerative diseases that lead to progressive neurological decline. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability.
We aim to delineate the core clinical, imaging, and molecular features of pediatric onset hereditary spastic paraplegia. This registry and natural history study will facilitate an early diagnosis, enables counseling and anticipatory guidance of affected families and will help define clinically meaningful endpoints for future interventional trials. Samples will be collected for the purpose of molecular and cellular investigation that will help identify biomarkers and novel targets for therapy. The samples and clinical information will be housed in the Translational Neuroscience Center and a secure REDcap database, respectively; both located in Boston Children's Hospital (BCH), but will be available to investigators around the world after approval.
The objectives of this protocol are to (1) To systematically document the clinical presentation and natural history of early-onset forms of HSP and (2) To facilitate an early diagnosis, enable counseling and anticipatory guidance of affected families and help define clinically meaningful endpoints for future interventional traits.
Specifically, the aims are to:
The study population consists of male and female patients up to the age of 30 years old with a clinical and molecular diagnosis of hereditary spastic paraplegia and/or their family members of interest (if applicable).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study population consists of male and female patients up to the age of 30 years old with a clinical and molecular diagnosis of hereditary spastic paraplegia and/or their family members of interest (if applicable).
Establishment of disease spectrum
Establish the disease spectrum through a cross-sectional analysis of clinical, imaging and molecular data
Time frame: Through study completion, an average of 1 year
Establishment of longitudinal data
Establish the natural history of early-onset HSP through longitudinal clinician- and patient-reported outcome measures
Time frame: Through study completion, an average of 1 year
Creation of biorepository
Create a biorepository (blood samples, fibroblasts, induced pluripotent stem cells)
Time frame: Through study completion, an average of 1 year
Creation of patient registry
Create a registry that allows for re-identification and re-contact of participants by appropriate investigators
Time frame: Through study completion, an average of 1 year
Started Apr 2020 (actual). Primary completion is estimated for Dec 2030, 128 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spastic Paraplegia, Hereditary →